Lasa Supergenerics touches roof on getting FDA’s nod to manufacture Progesterone

13 Apr 2020 Evaluate

Lasa Supergenerics is locked at upper circuit limit at Rs. 36.65, up by 1.70 points or 4.86% from its previous closing of Rs. 34.95 on the BSE.

The scrip opened at Rs. 36.65 and has touched a high and low of Rs. 36.65 and Rs. 36.65 respectively. So far 750 shares were traded on the counter.

The BSE group 'T' stock of face value Rs. 10 has touched a 52 week high of Rs. 49.70 on 28-Feb-2020 and a 52 week low of Rs. 9.48 on 06-Aug-2019.

Last one week high and low of the scrip stood at Rs. 36.65 and Rs. 31.50 respectively. The current market cap of the company is Rs. 142.15 crore.

The promoters holding in the company stood at 36.80%, while Institutions and Non-Institutions held 0.03% and 63.17% respectively.

Lasa Supergenerics has forayed into the hormone and steroid API segment for Human application with its approval from the Food and Drug Administration (FDA) authorities to manufacture Progesterone, a steroid hormone, at its WHO GMP certified facility at Mahad Industrial Area. The trial batches have already been carried out and the company is in good stead to start manufacturing from the current month itself.

Lasa Supergenerics is pioneer and amongst the leading players in the manufacturing of APIs in India through its catalyst chemistry expertise and fully backward integrated unit.


Lasa Supergenerics Share Price

9.90 -0.10 (-1.00%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×